My best advice would be just to call the FDA's Center for Biologics Evaluation & Research at 240-402-7800 or 301-796-3400; I've called before and they're pretty friendly.
This is something I learned after the whole SEC/FINRA ex-date thing, it's better to call and get a definitive answer; rules aren't always black and white.